Melatonin’s Beneficial Effects in Hepatic Injury



Melatonin is not only synthesized in the pineal gland, but its synthesis has also been described in numerous peripheral organs such as the retina, bone marrow, skin, Harderian gland, platelets, lymphocytes, testes, and gastrointestinal tract. Melatonin also plays a role as a free radical scavenger being a highly effective antioxidant. Several studies have demonstrated the effect of melatonin as an antioxidant to clear off oxidative damage in toxic liver injury. Melatonin administration appears to lower the increase in serum enzyme levels of aspartate transaminase, alanine transaminase, lactate dehydrogenase, alkaline phosphatase, γ- glutamyl transferase, and bilirubin after almost all types of injury, denoting that the extent of cell damage was reduced. According to current evidences, it seems possible that the strong protective effects of melatonin are mediated by the melatonin receptors in the liver as the absence of melatonin receptors impedes the protective action of melatonin administration. However, more studies are needed to confirm these beneficial effects.


Pineal Gland Ischemia Reperfusion Nonalcoholic Fatty Liver Disease Melatonin Receptor Melatonin Administration 


  1. 1.
    Abdel-Mawla AA, Fadali GA, Youssef EA, Eliwa HE. Induction of hepatocellular carcinoma in mice and the role of melatonin. J Basic Appl Zool. 2013;66:206–22.Google Scholar
  2. 2.
    Abdel-Wahab MH, Abd-Allah ARA. Possible protective effect of melatonin and/or desferrioxamine against streptozotocin-induced hyperglycaemia in mice. Pharmacol Res. 2001;41:533–7.CrossRefGoogle Scholar
  3. 3.
    Acuña-Castroviejo D, Escames G, Rodríguez MI, López LC. Melatonin role in the mitochondrial function. Front Biosci. 2007;12:947–63.CrossRefPubMedGoogle Scholar
  4. 4.
    Arteel GE. Alcohol-induced oxidative stress in the liver: in vivo measurements. Methods Mol Biol. 2008;447:185–97.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Axelrod J, Wurtman RJ. Photic and neural control of indoleamine metabolism in the rat pineal gland. Adv Pharmacol. 1968;6:157–66.CrossRefPubMedGoogle Scholar
  6. 6.
    Calvo JR, Reiter RJ, Garcia JJ, Ortiz GG, Tan DX, Karbownik M. Characterization of the protective effects of melatonin and related indoles against alpha-naphthylisothiocyanate-induced liver injury in rats. J Cell Biochem. 2001;80:461–70.CrossRefPubMedGoogle Scholar
  7. 7.
    Cardinali DP, Pevet P. Basic aspects of melatonin action. Sleep Med Rev. 1998;2:175–90.CrossRefPubMedGoogle Scholar
  8. 8.
    Carpentieria A, Díaz de Barbozaa G, Arecoa V, Lópeza MP, Tolosa de Talamoni N. New perspectives in melatonin uses. Pharmacol Res. 2012;65:437–44.CrossRefGoogle Scholar
  9. 9.
    Claustrat B, Brun J, Chazot G. The basic physiology and pathophysiology of melatonin. Sleep Med Rev. 2005;9:11–24.CrossRefPubMedGoogle Scholar
  10. 10.
    Clavien PA, Selzner M, Rüdiger HA, Graf R, Kadry Z, Rousson V, Jochum W. A prospective randomized study in 100 consecutive patients undergoing major liver resection with versus without ischemic preconditioning. Ann Surg. 2003;238:843–50.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Crespo I, Miguel BS, Laliena A, Alvarez M, Culebras JM, Gonzalez-Gallego J, Tunon MJ. Melatonin prevents the decreased activity of antioxidant enzymes and activates nuclear erythroid 2-related factor 2 signaling in an animal model of fulminant hepatic failure of viral origin. J Pineal Res. 2010;49:193–200.PubMedGoogle Scholar
  12. 12.
    Dey A, Cederbaum AI. Alcohol and oxidative liver injury. Hepatology. 2006;43:S63–74.CrossRefPubMedGoogle Scholar
  13. 13.
    Ding SY, Shen ZF, Chen YT, Sun SJ, Liu Q, Xie MZ. Pioglitazone can ameliorate insulin resistance in low-dose streptozotocin and high sucrose–fat diet induced obese rats. Acta Pharmacol Sin. 2005;26:575–80.CrossRefPubMedGoogle Scholar
  14. 14.
    Dubocovich ML, Markowska M. Functional MT1 and MT2 melatonin receptors in mammals. Endocrine. 2005;27:101–10.CrossRefPubMedGoogle Scholar
  15. 15.
    El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology. 2007;132:2557–76.CrossRefPubMedGoogle Scholar
  16. 16.
    El-Sokkary GH, Abdel-Rahman GH, Kamel ES. Melatonin protects against lead-induced hepatic and renal toxicity in male rats. Toxicology. 2005;213:25–33.CrossRefPubMedGoogle Scholar
  17. 17.
    El-Sokkary GH, Khidr BM, Younes HA. Role of melatonin in reducing hypoxia-induced oxidative stress and morphological changes in the liver of male mice. Eur J Pharmacol. 2006;540:107–14.CrossRefPubMedGoogle Scholar
  18. 18.
    El-Sokkary GH, Cuzzocrea S, Reiter RJ. Effect of chronic nicotine administration on the rat lung and liver: beneficial role of melatonin. Toxicology. 2007;239:60–7.CrossRefPubMedGoogle Scholar
  19. 19.
    El-Sokkary GH. Melatonin and vitamin C administration ameliorate diazepam-induced oxidative stress and cell proliferation in the liver of rats. Cell Prolif. 2008;41:168–76.CrossRefPubMedGoogle Scholar
  20. 20.
    El-Sokkary GH, Nafady AA, Shabash EH. Melatonin administration ameliorates cadmium-induced oxidative stress and morphological changes in the liver of rat. Ecotoxicol Environ Saf. 2010;73:456–63.CrossRefPubMedGoogle Scholar
  21. 21.
    Fan LL, Sun GP, Wei W, Wang ZG, Ge L, Fu WZ, Wang H. Melatonin and doxorubicin synergistically induce cell apoptosis in human hepatoma cell lines. World J Gastroenterol. 2010;16:1473–8.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Finocchiaro LM, Glikin GC. Intracellular melatonin distribution in cultured cell lines. J Pineal Res. 1998;24:22–34.CrossRefPubMedGoogle Scholar
  23. 23.
    Francis PL, Leone AM, Young IM, Stovell P, Silman RE. Gas chromatographic-mass spectrometric assay for 6-hydroxymelatonin sulfate and 6-hydroxymelatonin glucuronide in urine. Clin Chem. 1987;33:453–7.PubMedGoogle Scholar
  24. 24.
    Friedman SL. Seminars in medicine of the Beth Israel Hospital, Boston. The cellular basis of hepatic fibrosis. Mechanisms and treatment strategies. N Engl J Med. 1993;328:1828–35.CrossRefPubMedGoogle Scholar
  25. 25.
    Galano A, Tan DX, Reiter RJ. Melatonin as a natural ally against oxidative stress: a physicochemical examination. J Pineal Res. 2011;51:1–16.CrossRefPubMedGoogle Scholar
  26. 26.
    Gomez-Moreno G, Guardia J, Ferrera MJ, Cutando A, Reiter RJ. Melatonin in diseases of the oral cavity. Oral Dis. 2010;16:242–7.CrossRefPubMedGoogle Scholar
  27. 27.
    Güney S, Cuma A, Öztürk G, Akbulut KG, Karasu C. Comparison of melatonin effect on oxidant status and antioxidant capacity in liver and heart of young and aged rats. Int J Gerontol. 2013;7:45–9.CrossRefGoogle Scholar
  28. 28.
    Hardeland R, Cardinali DP, Srinivasan V, Spence DW, Brown GM, Pandi-Perumal SR. Melatonin—a pleiotropic, orchestrating regulator molecule. Prog Neurobiol. 2001;93:350–84.CrossRefGoogle Scholar
  29. 29.
    Hardeland R. Antioxidative protection by melatonin: multiplicity of mechanisms from radical detoxification to radical avoidance. Endocrine. 2005;27:119–30.CrossRefPubMedGoogle Scholar
  30. 30.
    Hardeland R, Pandi-Perumal SR, Cardinali DP. Melatonin. Int J Biochem Cell Biol. 2006;38:313–6.CrossRefPubMedGoogle Scholar
  31. 31.
    Hardeland R, Poeggeler B. Melatonin beyond its classical functions. Open Physiol J. 2008;1:1–23.CrossRefGoogle Scholar
  32. 32.
    Hardeland R. Melatonin: signaling mechanisms of a pleiotropic agent. Biofactors. 2009;35:183–92.CrossRefPubMedGoogle Scholar
  33. 33.
    Hardeland R, Coto-Montes A. New vistas on oxidative damage and aging. Open Biol J. 2010;3:39–52.CrossRefGoogle Scholar
  34. 34.
    Hirata F, Hayaishi O, Tokuyama T, Seno S. In vitro and in vivo formation of two new metabolites of melatonin. J Biol Chem. 1974;249:1311–3.PubMedGoogle Scholar
  35. 35.
    Hu S, Yin S, Jiang X, Huang D, Shen G. Melatonin protects against alcoholic liver injury by attenuating oxidative stress, inflammatory response, and apoptosis. Eur J Pharmacol. 2009;616:287–92.CrossRefPubMedGoogle Scholar
  36. 36.
    Iguchi H, Kato KI, Ibayashi H. Melatonin serum levels and metabolic clearance rate in patients with liver cirrhosis. J Clin Endocrinol Metab. 1982;54:1025–7.CrossRefPubMedGoogle Scholar
  37. 37.
    Jaeschke H, Farhood A. Neutrophil and Kupffer cell-induced oxidant stress and ischemia-reperfusion injury in rat liver. Am J Physiol. 1991;260:355–62.Google Scholar
  38. 38.
    Ji C, Deng Q, Kaplowitz N. Role of TNF-alpha in ethanol-induced hyperhomocysteinemia and murine alcoholic liver injury. Hepatology. 2004;40:442–51.CrossRefPubMedGoogle Scholar
  39. 39.
    Jou MJ, Peng TI, Reiter RJ, Jou SB, Wu HY, Wen ST. Visualization of the antioxidative effects of melatonin at the mitochondrial level during oxidative stress-induced apoptosis of rat brain astrocytes. J Pineal Res. 2004;37:55–70.CrossRefPubMedGoogle Scholar
  40. 40.
    Jung KH, Hong SW, Zheng HM, Lee DH, Hong SS. Melatonin downregulates nuclear erythroid 2-related factor 2 and nuclear factor-kappaB during prevention of oxidative liver injury in a dimethylnitrosamine model. J Pineal Res. 2009;47:173–83.CrossRefPubMedGoogle Scholar
  41. 41.
    Jung KH, Hong SW, Zheng HM, Lee HS, Lee H, Lee DH, Lee SY, Hong SS. Melatonin ameliorates cerulein-induced pancreatitis by the modulation of nuclear erythroid 2-related factor 2 and nuclear factor-kappaB in rats. J Pineal Res. 2010;48:239–50.CrossRefPubMedGoogle Scholar
  42. 42.
    Kang JW, Koh EJ, Lee SM. Melatonin protects liver against ischemia and reperfusion injury through inhibition of toll-like receptor signalling pathway. J Pineal Res. 2011;50:403–11.CrossRefPubMedGoogle Scholar
  43. 43.
    Kireev RA, Cuesta S, Ibarrola C, Bela T, Gonzalez EM, Vara E, Tresguerres JAF. Age-related differences in hepatic ischemia/reperfusion: gene activation, liver injury, and protective effect of melatonin. J Surg Res. 2012;178:922–34.CrossRefPubMedGoogle Scholar
  44. 44.
    Kitada T, Seki S, Iwai S, Yamada T, Sakaguchi H, Wakasa K. In situ detection of oxidative DNA damage, 8-hydroxydeoxyguanosine, in chronic human liver disease. J Hepatol. 2001;35:613–8.CrossRefPubMedGoogle Scholar
  45. 45.
    Korkmaz GG, Uzun H, Cakatay U, Aydin S. Melatonin ameliorates oxidative damage in hyperglycemia-induced liver injury. Clin Invest Med. 2012;35:370–7.Google Scholar
  46. 46.
    Kugelmas M, Hill DB, Vivian B, Marsano L, McClain CJ. Cytokines NASH: a pilot study of the effects of lifestyle modification and vitamin E. Hepatology. 2003;38:413–9.CrossRefPubMedGoogle Scholar
  47. 47.
    Kurcer Z, Oguz E, Iraz M, Fadillioglu E, Baba F, Koksal M, Olmez E. Melatonin improves methanol intoxication induced oxidative liver injury in rats. J Pineal Res. 2007;43:42–9.CrossRefPubMedGoogle Scholar
  48. 48.
    Lane N. Mitochondrial disease: powerhouse of disease. Nature. 2006;440:600–2.CrossRefPubMedGoogle Scholar
  49. 49.
    Latry P, Bioulac-Sage P, Echinard E, Gin H, Boussarie L, Grimaud JA, Balabaud C. Perisinusoidal fibrosis and basement membrane-like material in the livers of diabetic patients. Hum Pathol. 1987;18:775–80.CrossRefPubMedGoogle Scholar
  50. 50.
    Le Couteur DG, Rivory LP, Pond SM. The effects of aging and nutritional state on hypoxia-reoxygenation injury in the perfused rat liver. Transplantation. 1994;58:531–6.CrossRefPubMedGoogle Scholar
  51. 51.
    Lee KS, Buck M, Houglum K, Chojkier M. Activation of hepatic stellate cells by TGF alpha and collagen type I is mediated by oxidative stress through c-myb expression. J Clin Invest. 1995;96:2461–8.CrossRefPubMedPubMedCentralGoogle Scholar
  52. 52.
    Lenk SE, Bhat D, Blakeney W, Dunn Jr WA. Effects of streptozotocin-induced diabetes on rough endoplasmic reticulum and lysosomes of rat liver. Am J Physiol. 1992;263:E856–62.PubMedGoogle Scholar
  53. 53.
    Lentsch AB, Kato A, Yoshidome H, McMasters KM, Edwards MJ. Inflammatory mechanisms and therapeutic strategies for warm hepatic ischemia/reperfusion injury. Hepatology. 2000;32:169–73.CrossRefPubMedGoogle Scholar
  54. 54.
    Lerner AB, Case JD, Takahashi Y, Lee TH, Mori W. Isolation of melatonin, the pineal gland factor that lightens melanocytes. J Am Chem Soc. 1958;80:2587–92.CrossRefGoogle Scholar
  55. 55.
    Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc. 1980;55:434–8.PubMedGoogle Scholar
  56. 56.
    Macchi MM, Bruce JN. Human pineal physiology and functional significance of melatonin. Front Neuroendocrinol. 2004;25:177–95.CrossRefPubMedGoogle Scholar
  57. 57.
    Maritim AC, Moore BH, Sanders RA, Watkins III JB. Effects of melatonin on oxidative stress in streptozotocin-induced diabetic rats. Int J Toxicol. 1999;18:161–6.CrossRefGoogle Scholar
  58. 58.
    Mathes AM. Hepatoprotective actions of melatonin: possible mediation by melatonin receptors. World J Gastroenterol. 2010;16:6087–97.CrossRefPubMedPubMedCentralGoogle Scholar
  59. 59.
    Mayo JC, Sainz RM, Tan DX, Hardeland R, Leon J, Rodriguez C, Reiter RJ. Anti-inflammatory actions of melatonin and its metabolites, N1-acetyl-N2-formyl-5-methoxykynuramine (AFMK) and N1-acetyl-5-methoxykynuramine (AMK), in macrophages. J Neuroimmunol. 2005;165:139–49.CrossRefPubMedGoogle Scholar
  60. 60.
    Meki AR, Hussein AA. Melatonin reduces oxidative stress induced by ochratoxin A in rat liver and kidney. Comp Biochem Physiol C Toxicol Pharmacol. 2001;130:305–13.CrossRefPubMedGoogle Scholar
  61. 61.
    Menendez-Pelaez A, Reiter RJ. Distribution of melatonin in mammalian tissues: the relative importance of nuclear versus cytosolic localization. J Pineal Res. 1993;15:59–69.CrossRefPubMedGoogle Scholar
  62. 62.
    Messner M, Huether G, Lorf T, Ramadori G, Schworer H. Presence of melatonin in the human hepatobiliary–gastrointestinal tract. Life Sci. 2001;69:543–51.CrossRefPubMedGoogle Scholar
  63. 63.
    Mishra A, Paul S, Swarnakar S. Downregulation of matrix metalloproteinase-9 by melatonin during prevention of alcohol-induced liver injury in mice. Biochimie. 2001;93:854–66.CrossRefGoogle Scholar
  64. 64.
    Murawska-Ciaowicz E, Jethon Z, Magdalan J, Januszewska L, Podhorska-Okoowc M, Zawadzki M, Sozanski T, Dziegiel P. Effects of melatonin on lipid peroxidation and antioxidative enzyme activities in the liver, kidneys and brain of rats administered with benzo(a)pyrene. Exp Toxicol Pathol. 2011;63:97–103.CrossRefGoogle Scholar
  65. 65.
    Nagy LE. Recent insights into the role of the innate immune system in the development of alcoholic liver disease. Exp Biol Med (Maywood). 2003;228:882–90.Google Scholar
  66. 66.
    Nosjean O, Ferro M, Coge F, Beauverger P, Henlin JM, Lefoulon F, Fauchere JL, Delagrange P, Canet E, Boutin JA. Identification of the melatonin-binding site MT3 as the quinone reductase 2. J Biol Chem. 2000;275:31311–7.CrossRefPubMedGoogle Scholar
  67. 67.
    Notas G, Nifli AP, Kampa M, Vercauteren J, Kouroumalis E, Castanas E. Resveratrol exerts its antiproliferative effect on HepG2 hepatocellular carcinoma cells, by inducing cell cycle arrest, and NOS activation. Biochim Biophys Acta. 2006;1760:1657–66.CrossRefPubMedGoogle Scholar
  68. 68.
    Ohta Y, Kongo M, Kishikawa T. Melatonin exerts a therapeutic effect on cholestatic liver injury in rats with bile duct ligation. J Pineal Res. 2003;34:119–26.CrossRefPubMedGoogle Scholar
  69. 69.
    Ohta Y, Kongo M, Kishikawa T. Preventive effect of melatonin on the progression of alpha-naphthylisothiocyanate-induced acute liver injury in rats. J Pineal Res. 2003;34:185–93.CrossRefPubMedGoogle Scholar
  70. 70.
    Ohta Y, Imai Y, Matsura T, Yamada K, Tokunaga K. Successively postadministered melatonin prevents disruption of hepatic antioxidant status in rats with bile duct ligation. J Pineal Res. 2005;39:367–74.Google Scholar
  71. 71.
    Pan M, Song YL, Xu JM, Gan HZ. Melatonin ameliorates nonalcoholic fatty liver induced by high-fat diet in rats. J Pineal Res. 2006;41:79–84.CrossRefPubMedGoogle Scholar
  72. 72.
    Pandi-Perumal SR, Trakht I, Srinivasan V, Spence DW, Maestroni GJM, Zisapel N, Cardinali DP. Physiological effects of melatonin: role of melatonin receptors and signal transduction pathways. Prog Neurobiol. 2008;85:335–53.CrossRefPubMedGoogle Scholar
  73. 73.
    Park YJ, Park JG, Hiyakawa N, Lee YD, Kim SJ, Takemura A. Diurnal and circadian regulation of a melatonin receptor, MT1, in the golden rabbitfish, Siganus guttatus. Gen Comp Endocrinol. 2007;150:253–62.CrossRefPubMedGoogle Scholar
  74. 74.
    Parola M, Robino G. Oxidative stress-related molecules and liver fibrosis. J Hepatol. 2001;35:297–306.CrossRefPubMedGoogle Scholar
  75. 75.
    Pinzani M, Rombouts K. Liver fibrosis: from the bench to clinical targets. Dig Liver Dis. 2004;36:231–42.CrossRefPubMedGoogle Scholar
  76. 76.
    Poeggeler B, Thuermann S, Dose A, Schoenke M, Burkhardt S, Hardeland R. Melatonin’s unique radical scavenging properties – roles of its functional substituents as revealed by a comparison with its structural analogs. J Pineal Res. 2002;33:20–30.CrossRefPubMedGoogle Scholar
  77. 77.
    Reiter RJ. Pineal melatonin: cell biology of its synthesis and of its physiological interactions. Endocr Rev. 1991;12:151–80.CrossRefPubMedGoogle Scholar
  78. 78.
    Reiter RJ. Functional aspects of the pineal hormone melatonin in combating cell and tissue damage induced by free radicals. Eur J Endocrinol. 1996;134:412–20.CrossRefPubMedGoogle Scholar
  79. 79.
    Reiter RJ, Carneiro RC, Oh CS. Melatonin in relation to cellular antioxidative defense mechanisms. Horm Metab Res. 1997;29:363–72.CrossRefPubMedGoogle Scholar
  80. 80.
    Reiter RJ. Melatonin: clinical relevance. Best Pract Res Clin Endocrinol Metab. 2003;17:273–85.CrossRefPubMedGoogle Scholar
  81. 81.
    Reiter RJ, Tan DX, Gitto E, Sainz RM, Mayo JC, Leon J, Manchester LC, Vijayalaxmi, Kilic E, Kilic U. Pharmacological utility of melatonin in reducing oxidative cellular and molecular damage. Pol J Pharmacol. 2004;6:159–70.Google Scholar
  82. 82.
    Reiter RJ, Tan DX, Maldonado MD. Melatonin as an antioxidant: physiology versus pharmacology. J Pineal Res. 2005;39:215–6.CrossRefPubMedGoogle Scholar
  83. 83.
    Reppert SM, Godson C, Mahle CD, Weaver DR, Slaugenhaupt SA, Gusella JF. Molecular characterization of a second melatonin receptor expressed in human retina and brain: the Mel1b melatonin receptor. Proc Natl Acad Sci U S A. 1995;92:8734–8.CrossRefPubMedPubMedCentralGoogle Scholar
  84. 84.
    Reppert SM, Weaver DR, Ebisawa T. Cloning and characterization of a mammalian melatonin receptor that mediates reproductive and circadian responses. Neuron. 1994;13:1177–85.CrossRefPubMedGoogle Scholar
  85. 85.
    Rezzani R, Buffoli B, Rodella L, Stacchiotti A, Bianchi R. Protective role of melatonin in cyclosporine A-induced oxidative stress in rat liver. Int Immunopharmacol. 2005;5:1397–405.CrossRefPubMedGoogle Scholar
  86. 86.
    Rodriguez C, Mayo JC, Sainz RM, Antolin I, Herrera F, Martin V, Reiter RJ. Regulation of antioxidant enzymes: a significant role for melatonin. J Pineal Res. 2004;36:1–9.CrossRefPubMedGoogle Scholar
  87. 87.
    Rodríguez-Reynoso S, Leal C, Portilla E, Olivares N, Muñiz J. Effect of exogenous melatonin on hepatic energetic status during ischemia/reperfusion: possible role of tumor necrosis factor and nitric oxide. J Surg Res. 2001;100:141–9.CrossRefPubMedGoogle Scholar
  88. 88.
    Saada RA, Fath EL-Babb M, Shalaby AA. Attenuation of acute and chronic liver injury by melatonin in rats. J Taibah Univ Sci. 2013;7:88–96.CrossRefGoogle Scholar
  89. 89.
    Schaffazick SR, Pohlmann AR, de Cordova CA, Creczynski-Pasa TB, Guterres SS. Protective properties of melatonin-loaded nanoparticles against lipid peroxidation. Int J Pharm. 2005;289:209–13.CrossRefPubMedGoogle Scholar
  90. 90.
    Schaffazick SR, Pohlmann AR, Mezzalira G, Guterres SS. Development of nanocapsule suspensions and nanocapsule spray-dried powders containing melatonin. J Braz Chem Soc. 2006;17:562–9.CrossRefGoogle Scholar
  91. 91.
    Schaffazick SR, Siqueira IR, Badejo AS, Jornada DS, Pohlmann AR, Netto CA, Guterres SS. Incorporation in polymeric nanocapsules improves the antioxidant effect of melatonin against lipid peroxidation in mice brain and liver. Eur J Pharm Biopharm. 2008;69:64–71.CrossRefPubMedGoogle Scholar
  92. 92.
    Schemmer P, Nickkholgh A, Schneider H, Sobirey M, Weigand M, Koch M, Weitz J, Büchler MW. PORTAL: pilot study on the safety and tolerance of preoperative melatonin application in patients undergoing major liver resection: a double-blind randomized placebo-controlled trial. BMC Surg. 2008;8:2.CrossRefPubMedPubMedCentralGoogle Scholar
  93. 93.
    Sharma S, Rana SV. Melatonin improves liver function in benzene-treated rats. Arh Hig Rada Toksikol. 2013;64:33–41.CrossRefPubMedGoogle Scholar
  94. 94.
    Sigala F, Theocharis S, Sigalas K, Markantonis-Kyroudis S, Papalabros E, Triantafyllou A, Kostopanagiotou G, Andreadou I. Therapeutic value of melatonin in an experimental model of liver injury and regeneration. J Pineal Res. 2006;40:270–9.CrossRefPubMedGoogle Scholar
  95. 95.
    Skene DJ, Papagiannidou E, Hashemi E, Snelling J, Lewis DF, Fernandez M, Ioannides C. Contribution of CYP1A2 in the hepatic metabolism of melatonin: studies with isolated microsomal preparations and liver slices. J Pineal Res. 2001;31:333–42.CrossRefPubMedGoogle Scholar
  96. 96.
    Slominski RM, Reiter RJ, Schlabritz-Loutsevitch N, Ostrom RS, Slominski AT. Melatonin membrane receptors in peripheral tissues: distribution and functions. Mol Cell Endocrinol. 2012;351:152–66.CrossRefPubMedPubMedCentralGoogle Scholar
  97. 97.
    Smirnov AN. Nuclear melatonin receptors. Biochemistry (Mosc). 2001;66:19–26.CrossRefGoogle Scholar
  98. 98.
    Stehbens WE. Oxidative stress, toxic hepatitis, and antioxidants with particular emphasis on zinc. Exp Mol Pathol. 2003;75:265–76.CrossRefPubMedGoogle Scholar
  99. 99.
    Subramanian P, Mirunalini S, Dakshayani K, Pandi-Perumal SR, Trakht I, Cardinali DP. Prevention by melatonin of hepatocarcinogenesis in rats injected with N-nitrosodiethylamine. J Pineal Res. 2007;43:305–12.CrossRefPubMedGoogle Scholar
  100. 100.
    Tahan V, Ozaras R, Canbakan B, Uzun H, Aydin S, Yildirim B, Aytekin H, Ozbay G, Mert A, Senturk H. Melatonin reduces dimethylnitrosamine-induced liver fibrosis in rats. J Pineal Res. 2004;37:78–84.CrossRefPubMedGoogle Scholar
  101. 101.
    Tahan V, Atug O, Akin H, Eren F, Tahan G, Tarcin O, Uzun H, Ozdogan O, Tarcin O, Imeryuz N, Ozguner F, Celikel C, Avsar E, Tozun N. Melatonin ameliorates methionine- and choline-deficient diet-induced nonalcoholic steatohepatitis in rats. J Pineal Res. 2009;46:401–7.CrossRefPubMedGoogle Scholar
  102. 102.
    Tahan G, Akin H, Aydogan F, Ramadan SS, Yapicier O, Tarcin O, Uzun H, Tahan V, Zengin K. Melatonin ameliorates liver fibrosis induced by bile-duct ligation in rats. Can J Surg. 2010;53:313–8.PubMedPubMedCentralGoogle Scholar
  103. 103.
    Tan D, Manchester LC, Reiter RJ, Qi W, Hanes MA, Farley NJ. High physiological levels of melatonin in the bile of mammals. Life Sci. 1999;65:2523–9.CrossRefPubMedGoogle Scholar
  104. 104.
    Tan DX, Poeggeler B, Reiter RJ, Chen LD, Chen S, Manchester LC, Barlow-Walden LR. The pineal hormone melatonin inhibits DNA–adduct formation induced by the chemical carcinogen safrole in vivo. Cancer Lett. 1993;70:65–71.CrossRefPubMedGoogle Scholar
  105. 105.
    Tan DX, Reiter RJ, Chen LD, Poeggeler B, Manchester LC, Barlow-Walden LR. Both physiological and pharmacological levels of melatonin reduce DNA adduct formation induced by the carcinogen safrole. Carcinogenesis. 1994;15:215–8.CrossRefPubMedGoogle Scholar
  106. 106.
    Taysi S, Koc M, Buyukokuroglu ME, Altinkaynak K, Sahin YN. Melatonin reduces lipid peroxidation and nitric oxide during irradiation-induced oxidative injury in the rat liver. J Pineal Res. 2003;34:173–7.CrossRefPubMedGoogle Scholar
  107. 107.
    Tricoire H, Moller M, Chemineau P, Malpaux B. Origin of cerebrospinal fluid melatonin and possible function in the integration of photoperiod. Reprod Suppl. 2003;61:311–21.PubMedGoogle Scholar
  108. 108.
    Vidali M, Stewart SF, Albano E. Interplay between oxidative stress and immunity in the progression of alcohol-mediated liver injury. Trends Mol Med. 2008;14:63–71.CrossRefPubMedGoogle Scholar
  109. 109.
    Waldhauser F, Frisch H, Waldhauser M, Weiszenbacher G, Zeitlhuber U, Wurtman R. Fall in nocturnal serum melatonin during prepuberty and pubescence. Lancet. 1984;1:362–5.CrossRefPubMedGoogle Scholar
  110. 110.
    Wang H, Weit W, Wang NP, Gui SY, Wu L, Sun WY, Xu SY. Melatonin ameliorates carbon tetrachloride-induced hepatic fibrogenesis in rats via inhibition of oxidative stress. Life Sci. 2005;77:1902–15.CrossRefPubMedGoogle Scholar
  111. 111.
    Williams R. Global challenges in liver disease. Hepatology. 2006;44:521–6.CrossRefPubMedGoogle Scholar
  112. 112.
    Winiarska K, Fraczyk T, Malinska D, Drozak J, Bryla J. Melatonin attenuates diabetes-induced oxidative stress in rabbits. J Pineal Res. 2006;40:168–76.CrossRefPubMedGoogle Scholar
  113. 113.
    Yan JJ, Shen F, Wang K, Wu MC. Patients with advanced primary hepatocellular carcinoma treated by melatonin and transcatheter arterial chemoembolization: a prospective study. Hepatobiliary Pancreat Dis Int. 2002;1:183–6.PubMedGoogle Scholar
  114. 114.
    Yang QH, Xu JN, Xu RK, Pang SF. Inhibitory effects of melatonin on the growth of pituitary prolactin-secreting tumor in rats. J Pineal Res. 2006;40:230–5.CrossRefPubMedGoogle Scholar
  115. 115.
    Yin M, Wheeler MD, Kono H, Bradford BU, Gallucci RM, Luster MI, Thurman RG. Essential role of tumor necrosis factor alpha in alcohol-induced liver injury in mice. Gastroenterology. 1999;117:942–52.CrossRefPubMedGoogle Scholar
  116. 116.
    Yoshiuchi K, Kaneto H, Matsuoka TA, Kasami R, Kohno K, Iwawaki T, Nakatani Y, Yamasaki Y, Shimomura I, Matsuhisa M. Pioglitazone reduces ER stress in the liver: direct monitoring of in vivo ER stress using ER stress-activated indicator transgenic mice. Endocr J. 2009;56:1103–11.CrossRefPubMedGoogle Scholar
  117. 117.
    Yu EL, Schwimmer JB, Lavine JE. Non-alcoholic fatty liver disease: epidemiology, pathophysiology, diagnosis and treatment. Paediatr Child Health. 2010;20:26–9.CrossRefGoogle Scholar
  118. 118.
    Zaitone S, Hassan N, El-Orabi N, El-Awady ES. Pentoxifylline and melatonin in combination with pioglitazone ameliorate experimental non-alcoholic fatty liver disease. Eur J Pharmacol. 2011;662:70–7.CrossRefPubMedGoogle Scholar

Copyright information

© Springer India 2016

Authors and Affiliations

  1. 1.Department of Medical Biochemistry, Cerrahpasa Medical FacultyIstanbul UniversityIstanbulTurkey

Personalised recommendations